PHS Stock Chart & Stats
€4.92
-€0.05(-0.98%)
At close: 4:00 PM EDT
€4.92
-€0.05(-0.98%)
Day’s Range― - ―
52-Week Range€4.28 - €6.71
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€131.33M
Enterprise Value€1.44K
Total Cash (Recent Filing)€259.54M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)17.5
Beta0.26
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding27,120,820
10 Day Avg. Volume0
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Photocure ASA News
PHS FAQ
What was Photocure ASA’s price range in the past 12 months?
Photocure ASA lowest stock price was €4.28 and its highest was €6.71 in the past 12 months.
What is Photocure ASA’s market cap?
Photocure ASA’s market cap is €131.33M.
When is Photocure ASA’s upcoming earnings report date?
Photocure ASA’s upcoming earnings report date is Oct 28, 2026 which is in 46 days.
How were Photocure ASA’s earnings last quarter?
Photocure ASA released its earnings results on Jul 29, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of €0.002 by -€0.005.
Is Photocure ASA overvalued?
According to Wall Street analysts Photocure ASA’s price is currently Overvalued.
Does Photocure ASA pay dividends?
Photocure ASA does not currently pay dividends.
What is Photocure ASA’s EPS estimate?
Photocure ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Photocure ASA have?
Photocure ASA has 27,120,820 shares outstanding.
What happened to Photocure ASA’s price movement after its last earnings report?
Photocure ASA reported an EPS of -€0.003 in its last earnings report, missing expectations of €0.002. Following the earnings report the stock price went down -1.378%.
Which hedge fund is a major shareholder of Photocure ASA?
Currently, no hedge funds are holding shares in DE:PHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Photocure ASA
Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
PHS Company Deck
PHS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear commercial and strategic positives: double-digit product growth ex-FX in both North America and Europe, increasing installed base and active accounts, a healthy gross margin (~93%), completion of the Vesica acquisition to expand into precision diagnostics, major partnerships (Artera AI, Claritas), regulatory progress (FDA reclassification initiation and China approvals), and a raised near-term guide plus ambitious long-term growth and margin targets. Offsetting these were near-term profitability and cash impacts from investments: reported EBITDA and a small net loss in the quarter, increased operating expenses driven by business development, negative net cash flow in Q2 due to the Vesica acquisition, FX headwinds reducing reported U.S. growth, and a legal dispute with Asieris with outstanding milestone payments. Overall, the strategic and operational momentum and the high-quality margin profile of the core product line, combined with the potential upside from Vesica and regulatory catalysts, outweigh the near-term financial and execution risks highlighted.View all DE:PHS earnings summariesTechnical Analysis
Photocure ASA
―
―
Eagle Pharmaceuticals
―
Omeros
―
Tonix Pharma
―
Oncolytics Biotech
―
Pfizer
―